Incidence and Predictors of Esophagogastric Varices Bleeding in Patients with Hepatocellular Carcinoma in Lenvatinib
Liver Cancer · 2024 · 13 (2) · 215-226
DOI: 10.1159/000534127 ↗Kurz gefasst
Fachartikel in der Zeitschrift Liver Cancer, online erschienen am 14.09.2023. Verfasst von Massimo Iavarone und 44 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology and Hepatology, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Introduction
Lenvatinib is indicated for the forefront treatment of advanced hepatocellular carcinoma (aHCC), but its use may be limited by the risk of esophagogastric varices (EGV) bleeding. This study assessed the prevalence, predictors, and complications of EGV in aHCC patients treated with lenvatinib.
Methods
In this multicenter international retrospective study, cirrhotic patients treated with lenvatinib for aHCC, were enrolled if upper-gastrointestinal endoscopy was available within 6 months before treatment. Primary endpoint was the incidence of EGV bleeding during lenvatinib therapy; secondary endpoints were predictors for EGV bleeding, prevalence, and risk factors for the presence of EGV and high-risk EGV at baseline, as well as impact of EGV bleeding on patients’ survival.
Results
535 patients were enrolled in the study (median age: 72 years, 78% male, 63% viral etiology, 89% Child-Pugh A, 16% neoplastic portal vein thrombosis [nPVT], 56% Barcelona Clinic Liver Cancer-C): 234 had EGV (44%), 70 (30%) were at high risk and 59 were on primary prophylaxis. During lenvatinib treatment, 17 patients bled from EGV (3 grade 5), the 12-month cumulative incidence being 3%. The only baseline independent predictor of EGV bleeding was the presence of baseline high-risk EGV (hazard ratio: 6.94, 95% confidence interval [CI]: 2.23–21.57, p = 0.001). In these patients the 12-month risk was 17%. High-risk varices were independently associated with Child-Pugh B score (odds ratio [OR]: 2.12; 95% CI: 1.08–4.17, p = 0.03), nPVT (OR: 2.54; 95% CI: 1.40–4.61, p = 0.002), and platelets <150,000/μL (OR: 2.47; 95% CI: 1.35–4.50, p = 0.003).
Conclusion
In hepatocellular carcinoma patients treated with lenvatinib, the risk of EGV bleeding was mostly low but significant only in patients with high-risk EGV at baseline.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Gastroenterology and Hepatology, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
- Department of Medical Sciences, University of Pavia, Pavia, Italy.
- Department of Internal Medicine, Japanese Red Cross Himeji Hospital, Himeji, Japan.
- Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine, Kurume, Fukuoka, Japan.
- Department of Gastroenterology and Hepatology, Hokkaido University Graduate School of Medicine, Sapporo, Japan.
- Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
Zitieren
APA
Iavarone, M., Alimenti, E., Tada, T., Shimose, S., Suda, G., Yoo, C., Soldà, C., Piscaglia, F., Tosetti, G., Marra, F., Vivaldi, C., Conti, F., Schirripa, M., Iwamoto, H., Sho, T., Lee, S. H., Rizzato, M. D., Tonnini, M., Rimini, M., …, & Lampertico, P. (2024). Incidence and Predictors of Esophagogastric Varices Bleeding in Patients with Hepatocellular Carcinoma in Lenvatinib. Liver Cancer, 13(2), 215-226. https://doi.org/10.1159/000534127
Vancouver
Iavarone M, Alimenti E, Tada T, Shimose S, Suda G, Yoo C, et al. Incidence and Predictors of Esophagogastric Varices Bleeding in Patients with Hepatocellular Carcinoma in Lenvatinib. Liver Cancer. 2024;13(2):215-226. doi:10.1159/000534127
BibTeX
@article{Iavarone2024,
author = {Iavarone, Massimo and Alimenti, Eleonora and Tada, Toshifumi and Shimose, Shigeo and Suda, Goki and Yoo, Changhoon and Soldà, Caterina and Piscaglia, Fabio and Tosetti, Giulia and Marra, Fabio and Vivaldi, Caterina and Conti, Fabio and Schirripa, Marta and Iwamoto, Hideki and Sho, Takuya and Lee, So Heun and Rizzato, Mario Domenico and Tonnini, Matteo and Rimini, Margherita and Campani, Claudia and Masi, Gianluca and Foschi, Francesco and Bruccoleri, Mariangela and Kawaguchi, Takumi and Kumada, Takashi and Hiraoka, Atsushi and Atsukawa, Masanori and Fukunishi, Shinya and Ishikawa, Toru and Tajiri, Kazuto and Ochi, Hironori and Yasuda, Satoshi and Toyoda, Hidenori and Hatanaka, Takeshi and Kakizaki, Satoru and Kawata, Kazuhito and Tada, Fujimasa and Ohama, Hideko and Itokawa, Norio and Okubo, Tomomi and Arai, Taeang and Imai, Michitaka and Naganuma, Atsushi and Casadei-Gardini, Andrea and Lampertico, Pietro},
title = {Incidence and Predictors of Esophagogastric Varices Bleeding in Patients with Hepatocellular Carcinoma in Lenvatinib},
journal = {Liver Cancer},
year = {2024},
volume = {13},
number = {2},
pages = {215--226},
doi = {10.1159/000534127}
}
EUVIMED